Heat Biologics Inc. (HTBX)
Symbol Info
Listed Symbol HTBX
Name Heat Biologics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $4,650,672
Latest Fiscal EPS $-1.29
Price Info
21 Day Moving Average $0.5994
21 Day EMA $0.608250
50 Day Moving Average $0.6576
50 Day EMA $0.678390
200 Day EMA $1.141790
200 Day Moving Average 1.104310
52 Week High $2.24
52 Week Low $0.51
52 Week Change $-69.032600
Alpha -0.051144
Beta 1.7167
Standard Deviation 0.280432
R2 0.045111
Periods 60
Share Information
10 Day Average Volume 169,897
20 Day Average Volume 397,497
30 Day Average Volume 318,638
50 Day Average Volume 246,222
Outstanding Shares 34,066,652
Float Shares 31,647,747
Percent Float 92.90%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 28
Institute Holdings Date 2019-07-31
Institute Bought Previous 3 Months 190,965
Institute Holdings Percent 9.100000
Institute Sold Previous 3 Months 1,328,818
Insider Holdings Date 2019-07-31
Insider Bought Previous 3 Months -
Insider Holdings Percent 7.10%
Insider Sold Previous 3 Months -
Insiders Shares Owned 2,418,905
Price Change
7 Day Price Change $-0.0503
7 Day Percent Change -8.11%
21 Day Price Change $0.0098000
21 Day Percent Change 1.75%
30 Day Price Change $-0.0852
30 Day Percent Change -13.01%
Month To Date Price Change $-0.1404
Month To Date Percent -19.77%
90 Day Price Change $-0.2982
90 Day Percent Change -34.35%
Quarter To Date $-0.1152
Quarter To Date Percent -16.82%
180 Day Price Change $-0.8802
180 Day Percent Change -60.70%
200 Day Price Change $-0.8403
200 Day Percent Change -59.59%
Year To Date $-0.4102
Year To Date Percent -41.86%
Profile
Description Heat Biologics Inc is a US-based immuno-oncology company. It is engaged in developing therapies which activate a patient's immune system against cancer utilizing an engineered form of gp96. The group's T cell-stimulating therapeutic vaccine platform technologies, Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT), form the basis of its product candidates. Through ImPACT, it developed product candidates consisting of live, genetically-modified, irradiated human cancer cells which secrete tumor-associated antigens together with an immune response stimulator called gp96. Through ComPACT, the firm engineered product candidates that incorporate ligand fusion proteins targeting co-stimulatory receptors into the gp96-Ig expression vector.
Details
Issue Type CS
Market Cap $19,411,178
Sec Type EQS
Auditor BDO USA, LLP
Total Shares Outstanding 34,066,652
CEO Jeffrey Wolf
Employees 30
Last Audit UQ
Classification
CIK 0001476963
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 801 Capitola Drive
Durham, NC 27713
Website https://www.heatbio.com
Facisimile
Telephone +1 919 240-7133
Email investorrelations@heatbio.com
Key Ratios
Profitability
EBIT Margin -348
EBITDA Margin -343.4
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $6,494,911
Revenue Per Share $0.1907
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $-4,034,842
Price To Sales 2.988675
Price To Free Cash -1.3
PE High Last 5 Years -
Price To Book 0.7
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 1.0
Financial Strength
Total Debt To Equity 0.0
Int Coverage -
Current Ratio 5.7
Leverage Ratio 1.3
Quick Ratio 5.5
Long Term Debt To Capital 0.01
Assets
Receivables Turnover 113.0
Invoice Turnover -
Assets Turnover 0.10
Management Effectiveness
Return Assets -67.95
Return On Equity -105.81
Return On Capital -105.24
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
HTBX
Heat Biolo..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.